UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM6-K
REPORT OF FOREIGN PRIVATE ISSUER
PURSUANT TO RULE13a-16 or15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of July, 2019
Commission File Number:001-38452
MEREO BIOPHARMA GROUP PLC
(Translation of registrant’s name into English)
4th Floor, One Cavendish Place,
London, W1G 0QF, United Kingdom
(Address of principal executive office)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form20-F or Form40-F.
Form20-F ☒ Form40-F ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(1): ☐
Indicate by check mark if the registrant is submitting the Form6-K in paper as permitted by RegulationS-T Rule 101(b)(7): ☐
Mereo BioPharma Group plc
Holding(s) in Company
London, July 8, 2019 - Mereo BioPharma Group plc (AIM: MPH, NASDAQ: MREO), a clinical stage UK based biopharmaceutical company focused on rare diseases, today provided a regulatory news service (RNS) notification of major holdings through the London Stock Exchange plc, a copy of which is provided below.
RNS Number : 8439E
Mereo BioPharma Group plc
08 July 2019
TR-1: Standard form for notification of major holdings
NOTIFICATION OF MAJOR HOLDINGS(to be sent to the relevant issuerand to the FCA in Microsoft Word format if possible)i
|
1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attachedii:
| Mereo Biopharma Group PLC
| |
1b. Please indicate if the issuer is anon-UK issuer(please mark with an “X” if appropriate)
|
Non-UK issuer
| ||
2. Reason for the notification(please mark the appropriate box or boxes with an “X”)
|
An acquisition or disposal of voting rights
| ||
An acquisition or disposal of financial instruments
| ||
An event changing the breakdown of voting rights
| ||
Other (please specify)iii:
| X |
3. Details of person subject to the notification obligationiv
| ||
Name
| Woodford Investment Management Ltd
| |
City and country of registered office (if applicable)
| 9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
| |
4. Full name of shareholder(s) (if different from 3.)v
| ||
Name
| ||
City and country of registered office (if applicable)
| ||
5. Date on which the threshold was crossed or reachedvi:
| 05/07/2019
| |
6. Date on which issuer notified (DD/MM/YYYY):
| 08/07/2019
| |
7. Total positions of person(s) subject to the notification obligation
|
% of voting rights attached to shares (total of 8. A) | % of voting rights through financial instruments
| Total of both in % (8.A + 8.B) | Total number of voting rights of issuervii |
Resulting situation on the date on which threshold was crossed or reached
| 27.56% | 27.56% | 97,959,622 | |||||
Position of previous notification (if applicable)
| 30.46% | 30.46% |
8. Notified details of the resulting situation on the date on which the threshold was crossed or reachedviii | ||||||||
A: Voting rights attached to shares | ||||||||
Class/type of shares ISIN code (if possible) | Number of voting rightsix | % of voting rights | ||||||
Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | Direct (Art 9 of Directive 2004/109/EC) (DTR5.1) | Indirect (Art 10 of Directive 2004/109/EC) (DTR5.2.1) | |||||
GB00BZ4G2K23 | 26,999,540 | 27.56% | ||||||
SUBTOTAL 8. A | 26,999,540 | 27.56% |
B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a)) | ||||||||
Type of financial instrument | Expiration datex | Exercise/ Conversion Periodxi | Number of voting rights that may be acquired if the instrument is exercised/converted. | % of voting rights | ||||
SUBTOTAL 8. B 1 |
B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b)) | ||||||||||
Type of financial instrument | Expiration datex | Exercise/ Conversion Periodxi | Physical or cash settlementxii | Number of voting rights | % of voting rights | |||||
SUBTOTAL 8.B.2 |
9. Information in relation to the person subject to the notification obligation(please mark the applicable box with an “X”) | ||||||
Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuerxiii | X | |||||
Full chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held starting with the ultimate controlling natural person or legal entityxiv(please add additional rows as necessary) |
Namexv | % of voting rights if it equals or is higher than the notifiable threshold | % of voting rights through financial instruments if it equals or is higher than the notifiable threshold | Total of both if it equals or is higher than the notifiable threshold | |||
Woodford Investment Management Ltd | 27.56 | 0.00 | 27.56 |
10. In case of proxy voting, please identify: | ||||||
Name of the proxy holder | ||||||
The number and % of voting rights held | ||||||
The date until which the voting rights will be held |
11. Additional informationxvi | ||||||
Place of completion
| 9400 Garsington Road, Oxford, OX4 2HN, United Kingdom
| |||||
Date of completion
| 08/07/2019
|
Further Enquiries
Mereo | +44 (0)333 023 7300 | |||
Denise Scots-Knight, Chief Executive Officer | ||||
Richard Jones, Chief Financial Officer | ||||
Cantor Fitzgerald Europe (Nominated Adviser and Joint Broker to Mereo ) | +44 (0)20 7894 7000 | |||
Phil Davies | ||||
Will Goode | ||||
RBC Capital Markets (Joint Broker to Mereo ) | +44 (0)20 7653 4000 | |||
Rupert Walford | ||||
Jamil Miah | ||||
FTI Consulting (Public Relations Adviser to Mereo ) | ||||
Simon Conway | +44 (0)20 3727 1000 | |||
Brett Pollard | ||||
Ciara Martin | ||||
Burns McClellan (US Public Relations Adviser to Mereo ) | +01 (0) 212 213 0006 | |||
Lisa Burns | ||||
Steve Klass |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
Date: July 8, 2019
MEREO BIOPHARMA GROUP PLC | ||
By: | /s/ Charles Sermon | |
Name: | Charles Sermon | |
Title: | General Counsel |